Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial

The Lancet Oncology

Volumn 17, Issue 11, 2016, Pages 1543-1557

  Kerr, Rachel S ^a   Love, Sharon ^a   Segelov, Eva ^c   Johnstone, Elaine ^a   Falcon, Beverly ^d   Hewett, Peter ^e   Weaver, Andrew ^f   Church, David ^a   Scudder, Claire ^a   Pearson, Sarah ^a   Julier, Patrick ^a   Pezzella, Francesco ^a   Tomlinson, Ian ^b   Domingo, Enric ^a,b   Kerr, David J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d ELI LILLY AND COMPANY   (United States)

^e QUEEN ELIZABETH HOSPITAL   (Australia)

^f OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ADULT; AGE DISTRIBUTION; AMNESIA; ANEMIA; ANGINA PECTORIS; ANKLE EDEMA; ANOREXIA; ARTERIAL THROMBOEMBOLISM; ARTHRALGIA; ARTICLE; ATAXIA; BACKACHE; BLOOD CLOTTING DISORDER; BLURRED VISION; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CANCER ADJUVANT THERAPY; CANCER LOCALIZATION; CANCER STAGING; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CHEILITIS; CHEST INFECTION; CHEST TIGHTNESS; CLAUDICATION; COLITIS; COLORECTAL CANCER; CONFUSION; CONSCIOUSNESS DISORDER; CONSTIPATION; CONTROLLED STUDY; CYSTITIS; DEHYDRATION; DEPRESSION; DERMATITIS; DIARRHEA; DISEASE FREE SURVIVAL; DIZZINESS; DRUG DOSE REDUCTION; DRY EYE; DRY SKIN; DYSARTHRIA; DYSPEPSIA; DYSPHAGIA; DYSPHASIA; DYSPNEA; EAR INFECTION; FACIAL NERVE PARALYSIS; FAINTNESS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FISTULA; GASTROINTESTINAL DISEASE; GASTROINTESTINAL INFECTION; GEOGRAPHIC DISTRIBUTION; HAND FOOT SYNDROME; HEADACHE; HEARING IMPAIRMENT; HEART ARREST; HEART ATRIUM ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HEART PALPITATION; HEMATURIA; HEMIANOPIA; HEMOPTYSIS; HERNIA; HERPES SIMPLEX; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERKALEMIA; HYPERNATREMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPERURICEMIA; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOGLYCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; HYPOTENSION; HYPOTHERMIA; ILEITIS; INTENTION TO TREAT ANALYSIS; INTESTINE ISCHEMIA; INTESTINE OBSTRUCTION; INTESTINE PERFORATION; JOINT SWELLING; LETHARGY; LEUKOPENIA; LIFE EXPECTANCY; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCLE CRAMP; MYALGIA; MYOPATHY; NAIL DISEASE; NAUSEA; NEPHROLITHIASIS; NEURALGIA; NEUTROPENIA; OPEN STUDY; PAIN; PANCREATITIS; PANCYTOPENIA; PARESTHESIA; PERICARDITIS; PHASE 3 CLINICAL TRIAL; PHOTOSENSITIVITY; PRIORITY JOURNAL; PROTEINURIA; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; RASH; RECTUM HEMORRHAGE; SEIZURE; SENSORY NEUROPATHY; SEXUAL DYSFUNCTION; SIDE EFFECT; SINUS TACHYCARDIA; SKIN INFECTION; SKIN IRRITATION; SKIN ULCER; SUICIDAL IDEATION; TENESMUS; TOOTH DISEASE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UPPER GASTROINTESTINAL BLEEDING; UPPER RESPIRATORY TRACT INFECTION; URETERAL SPASM; URINARY TRACT INFECTION; VENOUS THROMBOEMBOLISM; VERTIGO; VISUAL IMPAIRMENT; WEAKNESS; WEIGHT GAIN; WOUND HEALING IMPAIRMENT; AGED; CLINICAL TRIAL; COLORECTAL NEOPLASMS; COMPARATIVE STUDY; MIDDLE AGED; MORTALITY;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; CAPECITABINE; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 84994796587     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(16)30172-3     Document Type: Article

References (19)

1. 1 Gray, R, Barnwell, J, McConkey, C, Williams, N, Kerr, DJ, QUASAR: a randomised study of adjuvant chemotherapy versus observation including 3239 colorectal cancer patients QUASAR Collaborative Group. Lancet 370 (2007), 2020–2029.
2. 2 Andre, T, Boni, C, Navarro, M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27 (2009), 3109–3116.
3. 3 Schmoll, HJ, Tabernero, J, Maroun, J, et al. Capecitabine plus oxaliplatin compared with fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results of the NO16968 randomized controlled phase III trial. J Clin Oncol 33 (2015), 3733–3740.
4. 4 Yothers, G, O'Connell, MJ, Allegra, CJ, et al. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol 29 (2011), 3768–3774.
5. 5 Hanahan, D, Weinberg, R, Hallmarks of cancer: the next generation. Cell 144 (2011), 644–649.
6. 6 Tebbutt, NC, Wilson, K, Gebski, VJ, Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. J Clin Oncol 28 (2010), 3191–3198.
7. 7 De Gramont, A, Van Cutsem, E, Schmoll, HJ, et al. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol 12 (2012), 1225–1233.
8. 8 Allegra, CJ, Yothers, G, O'Connell, MJ, et al. Bevacizumab in stage II–III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial. J Clin Oncol 31 (2013), 359–364.
9. 9 Pogue-Geile, K, Yothers, G, Taniyama, Y, et al. Defective mismatch repair and benefit from bevacizumab for colon cancer: findings from NSABP C-08. J Natl Cancer Inst 105 (2013), 989–992.
10. 10 Saltz, L, Niedzwiecki, D, Hollis, D, et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol 25 (2007), 3456–3461.
11. 11 Van Cutsem, E, Labianca, R, Bodoky, G, et al. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol 27 (2009), 3117–3125.
12. 12 Domingo, E, Ramamoorthy, R, Oukrif, D, et al. Use of multivariate analysis to suggest a new molecular classification of colorectal cancer. J Pathol 229 (2013), 441–448.
13. 13 Boland, CR, Thibodeau, SN, Hamilton, SR, et al. A National Cancer Institute Workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 58 (1998), 5248–5257.
14. 14 Danielsen, HE, Pradhan, M, Novelli, M, Revisiting tumour aneuploidy—the place of ploidy assessment in the molecular era. Nat Rev Clin Oncol 13 (2016), 291–304.
15. 15 Falcon, BL, Stewart, J, Ezell, S, et al. High-content multiplexed tissue imaging and quantification for cancer drug discovery. Drug Discov Today 18 (2013), 510–522.
16. 16 Ciocâlteu, A, Săftoiu, A, Cârţână, T, et al. Evaluation of new morphometric parameters of neoangiogenesis in human colorectal cancer using confocal laser endomicroscopy (CLE) and targeted panendothelial markers. PLoS One, 9, 2014, e91084.
17. 17 Smith, NR, Baker, D, Farren, M, et al. Tumor stromal architecture can define the intrinsic tumor response to VEGF-targeted therapy. Clin Cancer Res, 19, 2013, 6943.
18. 18 Sagaert, X, Van Cutsem, E, Tejpar, S, Prenen, H, De Hertogh, G, MSI versus MSS sporadic colorectal cancers: morphology, inflammation, and angiogenesis revisited. Proc Am Soc Clin Onc, 32, 2014 (abstr 495).
19. 19 Terme, M, Pernot, S, Marcheteau, E, et al. VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer. Cancer Res 73 (2013), 539–549.